POTENTIAL DRUG DELIVERY SYSTEMS AND DEVICE COMBINATION FOR THE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
DOI:
https://doi.org/10.22159/ijap.2025v17i2.53177Keywords:
Bronchodilators, GOLD, LABA, LAMA, Triple therapyAbstract
Chronic Obstructive Pulmonary Disease (COPD) presents with chronic lung inflammation and poorly reversible airflow limitation, necessitating bronchodilators for management. The Global Initiative for COPD recommends combining Long-Acting Beta-Agonists (LABAs) and Long-Acting Antimuscarinic Agents (LAMAs) for most COPD patients. Developing fixed LAMA/LABA combinations is crucial. Adding an Inhaled Corticosteroid (ICS) to this combination may offer additional benefits, including preventing exacerbations. The GOLD report emphasizes diagnosis, prevention, exacerbation management, and addressing comorbidities. It advocates for holistic COPD management integrating pharmacologic and non-pharmacologic approaches. Novel strategies like mono, dual, and triple therapies are recommended. The review highlights COPD's impact on COVID-19, comorbidities, and relevant patents concerning COPD and bronchodilators. The bronchodilator treatments may improve their efficacy in this critical aspect of COPD. Research shows that dual bronchodilation improves lung function and symptoms more consistently than mono-bronchodilation, while potentially lowering the risk of exacerbations and disease deterioration and having a similar safety profile.
Downloads
References
Quaderi SA, Hurst JR. The unmet global burden of COPD. Glob Health EpidemiolGenom. 2018;3. doi: 10.1017/gheg.2018.1. Cited: in: : PMID: 29868229.
Rahmad, Narasati S, Nugroho E, Witjaksono D, Lestari DI, Nugroho MB, Rachmawati S, Ridwan M. The role of pulmonary rehabilitation in acute exacerbations of chronic obstructive pulmonary disease. International Journal of Applied Pharmaceutics. 2020;12:39–40. doi: 10.22159/ijap.2020.v12s3.39466.
Khan S, Monika. Circadian Rhythms Regulated Asthma Treatment By Virtue of Pulsatile Drug Delivery System. International Journal of Applied Pharmaceutics. 2022;14:1–8. doi: 10.22159/ijap.2022v14i4.44395.
Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. The Lancet. 2022;399:2227–2242. doi: 10.1016/S0140-6736(22)00470-6. Cited: in: : PMID: 35533707.
Qureshi H, Sharafkhaneh A, Hanania NA. Chronic obstructive pulmonary disease exacerbations: Latest evidence and clinical implications. Ther Adv Chronic Dis. 2014;5:212–227. doi: 10.1177/2040622314532862.
Le Jemtel TH, Padeletti M, Jelic S. Diagnostic and Therapeutic Challenges in Patients With Coexistent Chronic Obstructive Pulmonary Disease and Chronic Heart Failure. J Am Coll Cardiol. 2007;49:171–180. doi: 10.1016/j.jacc.2006.08.046. Cited: in: : PMID: 17222727.
Barnes PJ. Muscarinic receptor subtypes: Implications for therapy. Agents Actions. 1993;43:243–252. doi: 10.1007/978-3-0348-7324-6_21. Cited: in: : PMID: 8368167.
Haddad EB, Mak JCW, Barnes PJ. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: Radioligand binding and autoradiographic mapping. Mol Pharmacol. 1994;45:899–907. Cited: in: : PMID: 8190106.
Skolnik NS, Nguyen TS, Shrestha A, Ray R, Corbridge TC, Brunton SA. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators. Postgrad Med. 2020;132:198–205. doi: 10.1080/00325481.2019.1702834. Cited: in: : PMID: 31900019.
Wedzicha JA, Decramer M, Seemungal TAR. The role of bronchodilator treatment in the prevention of exacerbations of COPD. European Respiratory Journal. 2012;40:1545–1554. doi: 10.1183/09031936.00048912. Cited: in: : PMID: 22835613.
Beeh KM. The role of bronchodilators in preventing exacerbations of chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2016;79:241–247. doi: 10.4046/trd.2016.79.4.241.
Singh D, Donohue JF, Boucot IH, Barnes NC, Compton C, Martinez FJ. Future concepts in bronchodilation for copd: Dual-versus monotherapy. European Respiratory Review. 2021;30. doi: 10.1183/16000617.0023-2021. Cited: in: : PMID: 34415847.
Soler-Cataluña JJ, Marzo M, Catalán P, Miralles C, Alcazar B, Miravitlles M. Validation of clinical control in COPD as a new tool for optimizing treatment. International Journal of COPD. 2018;13:3719–3731. doi: 10.2147/COPD.S178149. Cited: in: : PMID: 30532528.
Vogelmeier CF, Román-Rodríguez M, Singh D, Han MLK, Rodríguez-Roisin R, Ferguson GT. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med. 2020;166. doi: 10.1016/j.rmed.2020.105938. Cited: in: : PMID: 32250871.
O’driscoll BR, Babu KS, Chauhan AJ. Management of chronic obstructive pulmonary disease. Bmj. 2003;326:821. doi: 10.1136/bmj.326.7393.821. Cited: in: : PMID: 12689985.
Safka KA, Andrew McIvor R. Non-pharmacological management of chronic obstructive pulmonary disease. Ulster Medical Journal. 2015;84:13–21. Cited: in: : PMID: 25964698.
Alagha K, Palot A, Sofalvi T, Pahus L, Gouitaa M, Tummino C, Martinez S, Charpin D, Chanez P, Bourdin A. Long-acting muscarinic receptor antagonists for the treatment of chronic airway diseases. Ther Adv Chronic Dis. 2014;5:85–98. doi: 10.1177/2040622313518227.
Ko FW, Chan KP, Hui DS, Goddard JR, Shaw JG, Reid DW, Yang IA. Acute exacerbation of COPD. Respirology. 2016;21:1152–1165. doi: 10.1111/resp.12780. Cited: in: : PMID: 27028990.
Welte T. Optimising treatment for COPD - New strategies for combination therapy. Int J Clin Pract. 2009;63:1136–1149. doi: 10.1111/j.1742-1241.2009.02139.x. Cited: in: : PMID: 19624783.
Hunninghake GM, Cho MH, Tesfaigzi Y, Soto-Quiros ME, Avila L, Lasky-Su J, Stidley C, Melén E, Söderhäll C, Hallberg J, et al. MMP12, Lung Function, and COPD in High-Risk Populations . New England Journal of Medicine. 2009;361:2599–2608. doi: 10.1056/nejmoa0904006. Cited: in: : PMID: 20018959.
Venkatesan P. GOLD COPD report: 2023 update. Lancet Respir Med. 2023;11:18. doi: 10.1016/S2213-2600(22)00494-5. Cited: in: : PMID: 36462509.
Løkke A, Nielsen LP, Moberg M, Marså K, Titlestad IL, Kofod LM, Godtfredsen NS. Treatment of stable chronic obstructive pulmonary disease. UgeskrLaeger. 2019;180:2–6. doi: 10.2147/copd.s3483. Cited: in: : PMID: 19281074.
Wedzicha JA, Decramer M, Seemungal TAR. The role of bronchodilator treatment in the prevention of exacerbations of COPD. European Respiratory Journal. 2012;40:1545–1554. doi: 10.1183/09031936.00048912. Cited: in: : PMID: 22835613.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St. Rose E, Ballal S, McLaren J, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. New England Journal of Medicine. 2020;383:35–48. doi: 10.1056/nejmoa1916046. Cited: in: : PMID: 32579807.
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. New England Journal of Medicine. 2018;378:1671–1680. doi: 10.1056/nejmoa1713901. Cited: in: : PMID: 29668352.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St Rose E, Ballal S, McLaren J, et al. A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6 μg and 160/18/9.6 μg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. Respir Med. 2019;158:59–66. doi: 10.1016/j.rmed.2019.08.010. Cited: in: : PMID: 31605923.
D’Urzo AD, Singh D, Donohue JF, Chapman KR, Wise RA. Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. Expert Rev Respir Med. 2021;15:1093–1106. doi: 10.1080/17476348.2021.1920403. Cited: in: : PMID: 34137664.
King P. Role of arformoterol in the management of COPD. International Journal of COPD. 2008;3:385–391. doi: 10.2147/copd.s753. Cited: in: : PMID: 18990965.
Zheng J, Xu JF, Jenkins M, Assam PN, Wang L, Lipworth BJ. Glycopyrrolate/formoterol fumarate metered dose inhaler for maintenance-naïve patients with chronic obstructive pulmonary disease: A post-hoc analysis of the randomized PINNACLE trials. Respir Res. 2020;21. doi: 10.1186/s12931-020-1332-3. Cited: in: : PMID: 32164675.
Cazzola M, Bardaro F, Stirpe E. The role of indacaterol for chronic obstructive pulmonary disease (COPD). J Thorac Dis. 2013;5:559–566. doi: 10.3978/j.issn.2072-1439.2013.07.35. Cited: in: : PMID: 23991316.
Olodaterol-another LABA for COPD. Drug Ther Bull. 2015;53:42–45. doi: 10.1136/dtb.2015.4.0319. Cited: in: : PMID: 25858815.
Tashkin DP, Ohar JA, Koltun A, Allan R, Ward JK. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device. Pulm Med. 2021;2021. doi: 10.1155/2021/8881895. Cited: in: : PMID: 33815843.
Anzueto A, Miravitlles M. Tiotropium in chronic obstructive pulmonary disease - A review of clinical development. Respir Res. 2020;21. doi: 10.1186/s12931-020-01407-y. Cited: in: : PMID: 32727455.
Umeclidinium: Another LAMA for COPD. Drug Ther Bull. 2015;53:81–84. doi: 10.1136/dtb.2015.7.0340. Cited: in: : PMID: 26159701.
Yang IA, Brown JL, George J, Jenkins S, McDonald CF, McDonald VM, Phillips K, Smith BJ, Zwar NA, Dabscheck E. COPD-X australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Medical Journal of Australia. 2017;207:436–442. doi: 10.5694/mja17.00686. Cited: in: : PMID: 29129177.
Singh D. Pharmacological treatment of stable chronic obstructive pulmonary disease. Respirology. 2021;26:643–651. doi: 10.1111/resp.14046. Cited: in: : PMID: 33829619.
van der Molen T, Cazzola M. Beyond lung function in COPD management: Effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Primary Care Respiratory Journal. 2012;21:101–108. doi: 10.4104/pcrj.2011.00102.
Horita N, Goto A, Ota E, Nakashima K, Nagai K, Kaneko T. Long-acting muscarinic antagonist plus long-acting beta agonist versus long-acting beta agonist plus inhaled corticosteroid for stable chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2016;2016. doi: 10.1002/14651858.CD012066.
Janson C. Treatment with inhaled corticosteroids in chronic obstructive pulmonary disease. J Thorac Dis. 2020;12:1561–1569. doi: 10.21037/jtd.2020.02.51.
Tashkin D, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease (UPLIFT trial). Rev Port Pneumol. 2009;15:137–140. doi: 10.1016/s0873-2159(15)30121-5.
Tashkin DP, Ohar JA, Koltun A, Allan R, Ward JK. The Role of ICS/LABA Fixed-Dose Combinations in the Treatment of Asthma and COPD: Bioequivalence of a Generic Fluticasone Propionate-Salmeterol Device. Lazar Z, editor. Pulm Med. 2021;2021:1–7. doi: 10.1155/2021/8881895.
Busse WW, Shah SR, Somerville L, Parasuraman B, Martin P, Goldman M. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. Journal of Allergy and Clinical Immunology. 2008;121. doi: 10.1016/j.jaci.2008.03.019. Cited: in: : PMID: 18455221.
Berger WE. Mometasone furoate/formoterol in the treatment of persistent asthma. Expert Rev Respir Med. 2011;5:739–746. doi: 10.1586/ers.11.71. Cited: in: : PMID: 22082160.
Syed YY. Fluticasone furoate/vilanterol: A review of its use in patients with asthma. Drugs. 2015;75:407–418. doi: 10.1007/s40265-015-0354-5. Cited: in: : PMID: 25648266.
McKeage K, Keam SJ. Salmeterol fluticasone propionate: A review of its use in asthma. Drugs. 2009;69:1799–1828. doi: 10.2165/11202210-000000000-00000. Cited: in: : PMID: 19719334.
van Noord JA, Aumann JL, Janssens E, Smeets JJ, Zaagsma J, Mueller A, Cornelissen PJG. Combining tiotropium and salmeterol in COPD: Effects on airflow obstruction and symptoms. Respir Med. 2010;104:995–1004. doi: 10.1016/j.rmed.2010.02.017. Cited: in: : PMID: 20303247.
Vogelmeier C, Kardos P, Harari S, Gans SJM, Stenglein S, Thirlwell J. Formoterol mono- and combination therapy with tiotropium in patients with COPD: A 6-month study. Respir Med. 2008;102:1511–1520. doi: 10.1016/j.rmed.2008.07.020. Cited: in: : PMID: 18804362.
National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow). NICE Advice. 2018;1–78.
Richeldi L, Piraino A, Macagno F, Micarelli G, Ingrassia E. The impact of fixed triple therapy with beclometasone/formoterol/glycopyrronium on health status and adherence in chronic obstructive pulmonary disease (COPD) in an italian context of real life: The TRITRIAL study protocol. International Journal of COPD. 2021;16:159–166. doi: 10.2147/COPD.S286559. Cited: in: : PMID: 33536751.
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. The Lancet. 2018;391:1076–1084. doi: 10.1016/S0140-6736(18)30206-X. Cited: in: : PMID: 29429593.
Mahler DA, Buhl R, Lawrence D, McBryan D. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. PulmPharmacolTher. 2013;26:348–355. doi: 10.1016/j.pupt.2013.02.006. Cited: in: : PMID: 23434446.
Mahler DA, D’Urzo A, Bateman ED, Özkan SA, White T, Peckitt C, Lassen C, Kramer B. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: A randomised, double-blind comparison. Thorax. 2012;67:781–788. doi: 10.1136/thoraxjnl-2011-201140.
D’Urzo A, Rennard S, Kerwin E, Donohue JF, Lei A, Molins E, Leselbaum A. A randomised double-blind, placebo-controlled, long-term extension study of the efficacy, safety and tolerability of fixed-dose combinations of aclidinium/formoterol or monotherapy in the treatment of chronic obstructive pulmonary disease. Respir Med. 2017;125:39–48. doi: 10.1016/j.rmed.2017.02.008. Cited: in: : PMID: 28340861.
Ferguson GT, Taylor AF, Thach C, Wang Q, Schubert-Tennigkeit AA, Patalano F, Banerji D. Long-Term Maintenance Bronchodilation With Indacaterol/Glycopyrrolate Versus Indacaterol in Moderate-to-Severe COPD Patients: The FLIGHT 3 Study. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2016;3:716–728. doi: 10.15326/jcopdf.3.4.2016.0131.
O’Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, Xue W, Maltais F. Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. European Respiratory Journal. 2017;49. doi: 10.1183/13993003.01348-2016. Cited: in: : PMID: 28424359.
Maltais F, Singh S, Donald AC, Crater G, Church A, Goh AH, Riley JH. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: Two randomized, double-blind clinical trials. Ther Adv Respir Dis. 2014;8:169–181. doi: 10.1177/1753465814559209. Cited: in: : PMID: 25452426.
Martinez FJ, Rabe KF, Ferguson GT, Fabbri LM, Rennard S, Feldman GJ, Sethi S, Spangenthal S, Gottschlich GM, Rodriguez-Roisin R, et al. Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest. 2017;151:340–357. doi: 10.1016/j.chest.2016.11.028. Cited: in: : PMID: 27916620.
Jung KS, Park HY, Park SY, Kim SK, Kim YK, Shim JJ, Moon HS, Lee KH, Yoo JH, Lee S Do. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: A randomized controlled study. Respir Med. 2012;106:382–389. doi: 10.1016/j.rmed.2011.09.004. Cited: in: : PMID: 21975275.
Chatterjee A, Shah M, D’Souza AO, Bechtel B, Crater G, Dalal AA. Observational study on the impact of initiating tiotropium alone versus tiotropium with fluticasone propionate/salmeterol combination therapy on outcomes and costs in chronic obstructive pulmonary disease. Respir Res. 2012;13. doi: 10.1186/1465-9921-13-15. Cited: in: : PMID: 22340019.
Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592–598. doi: 10.1136/thx.2007.087213. Cited: in: : PMID: 18245142.
Maltais F, Hamilton A, Voß F, Maleki-Yazdi MR. Dose Determination for a Fixed-Dose Drug Combination: A Phase II Randomized Controlled Trial for Tiotropium/Olodaterol Versus Tiotropium in Patients with COPD. Adv Ther. 2019;36:962–968. doi: 10.1007/s12325-019-00911-y. Cited: in: : PMID: 30843141.
Bogart M, Stanford RH, Laliberté F, Germain G, Wu JW, Duh MS. Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population. International Journal of COPD. 2019;14:343–352. doi: 10.2147/COPD.S184653. Cited: in: : PMID: 30863037.
Gaduzo S, McGovern V, Roberts J, Scullion JE, Singh D. When to use single-inhaler triple therapy in COPD: A practical approach for primary care health care professionals. International Journal of COPD. 2019;14:391–401. doi: 10.2147/COPD.S173901. Cited: in: : PMID: 30863039.
Pascoe S, Barnes N, Brusselle G, Compton C, Criner GJ, Dransfield MT, Halpin DMG, Han MLK, Hartley B, Lange P, et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial. Lancet Respir Med. 2019;7:745–756. doi: 10.1016/S2213-2600(19)30190-0. Cited: in: : PMID: 31281061.
Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: A secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–442. doi: 10.1016/S2213-2600(15)00106-X. Cited: in: : PMID: 25878028.
Vanfleteren LEGW, Ullman A, Nordenson A, Andersson A, Andelid K, Fabbri LM. Triple therapy (ICS/LABA/LAMA) in COPD: Thinking out of the box. ERJ Open Res. 2019;5. doi: 10.1183/23120541.00185-2018.
Ritondo BL, Puxeddu E, Calzetta L, Cazzola M, Rogliani P. Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review. Expert OpinPharmacother. 2021;22:611–620. doi: 10.1080/14656566.2020.1845314. Cited: in: : PMID: 33131340.
COPD Global Initiative (2020) 2020 Report. Global Initiative for Chronic Obstructive Lung Disease.
Singh D, Fabbri LM, Corradi M, Georges G, Guasconi A, Vezzoli S, Petruzzelli S, Papi A. Extrafine triple therapy in patients with symptomatic COPD and history of one moderate exacerbation. European Respiratory Journal. 2019;53. doi: 10.1183/13993003.00235-2019. Cited: in: : PMID: 30792343.
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. The Lancet. 2017;389:1919–1929. doi: 10.1016/S0140-6736(17)30188-5. Cited: in: : PMID: 28385353.
Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. The Lancet. 2018;391:1076–1084. doi: 10.1016/S0140-6736(18)30206-X. Cited: in: : PMID: 29429593.
Gross N. The COPD Pipeline XXX. Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation. 2016;3:498–502. doi: 10.15326/jcopdf.3.1.2015.0181.
Lipson DA, Barnacle H, Birk R, Brealey N, Locantore N, Lomas DA, Ludwig-Sengpiel A, Mohindra R, Tabberer M, Zhu CQ, et al. FULFIL Trial: Once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196:438–446. doi: 10.1164/rccm.201703-0449OC. Cited: in: : PMID: 28375647.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747–758. doi: 10.1016/S2213-2600(18)30327-8. Cited: in: : PMID: 30232048.
Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, Agusti AA, Vogelmeier CF. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. Am J Respir Crit Care Med. 2021;203:24–36. doi: 10.1164/rccm.202009-3533SO. Cited: in: : PMID: 33146552.
Vestbo J, Papi A, Corradi M, Blazhko V, Montagna I, Francisco C, Cohuet G, Vezzoli S, Scuri M, Singh D. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. The Lancet. 2017;389:1919–1929. doi: 10.1016/S0140-6736(17)30188-5. Cited: in: : PMID: 28385353.
Tsiligianni I, Goodridge D, Marciniuk D, Hull S, Bourbeau J. Four patients with a history of acute exacerbations of COPD: Implementing the CHEST/Canadian Thoracic Society guidelines for preventing exacerbations. NPJ Prim Care Respir Med. 2015;25. doi: 10.1038/npjpcrm.2015.23. Cited: in: : PMID: 25950092.
Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018;6:747–758. doi: 10.1016/S2213-2600(18)30327-8. Cited: in: : PMID: 30232048.
Rabe KF, Martinez FJ, Ferguson GT, Wang C, Singh D, Wedzicha JA, Trivedi R, St. Rose E, Ballal S, McLaren J, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. New England Journal of Medicine. 2020;383:35–48. doi: 10.1056/nejmoa1916046. Cited: in: : PMID: 32579807.
Yu AP, Guérin A, Ponce De Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: Multiple versus single long-acting maintenance inhalers. J Med Econ. 2011;14:486–496. doi: 10.3111/13696998.2011.594123. Cited: in: : PMID: 21679019.
Gaduzo S, McGovern V, Roberts J, Scullion JE, Singh D. When to use single-inhaler triple therapy in COPD: A practical approach for primary care health care professionals. International Journal of COPD. 2019;14:391–401. doi: 10.2147/COPD.S173901. Cited: in: : PMID: 30863039.
Fabbri LM, Roversi S, Beghé B. Triple therapy for symptomatic patients with COPD. The Lancet. 2017;389:1864–1865. doi: 10.1016/S0140-6736(17)30567-6. Cited: in: : PMID: 28385354.
Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, MacNee W, et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine. 2010;363:1128–1138. doi: 10.1056/nejmoa0909883. Cited: in: : PMID: 20843247.
Han MLK, Quibrera PM, Carretta EE, Barr RG, Bleecker ER, Bowler RP, Cooper CB, Comellas A, Couper DJ, Curtis JL, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5:619–626. doi: 10.1016/S2213-2600(17)30207-2. Cited: in: : PMID: 28668356.
Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RCM, Coker-Schwimmer EJL, Rosen DL, Sista P, Lohr KN. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: A systematic review. Ann Intern Med. 2012;157:785–795. doi: 10.7326/0003-4819-157-11-201212040-00538. Cited: in: : PMID: 22964778.
Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGeralde M, Gibson P, Ohta K, O’Byrne P, Pedersen SE, et al. Global strategy for asthma management and prevention: GINA executive summary. European Respiratory Journal. 2008;31:143–178. doi: 10.1183/09031936.00138707. Cited: in: : PMID: 18166595.
Bender BG. Nonadherence to Asthma Treatment: Getting Unstuck. Journal of Allergy and Clinical Immunology: In Practice. 2016;4:849–851. doi: 10.1016/j.jaip.2016.07.007. Cited: in: : PMID: 27587318.
Mehta PP, Dhapte-Pawar VS. Repurposing drug molecules for new pulmonary therapeutic interventions. Drug Deliv Transl Res. 2021;11:1829–1848. doi: 10.1007/s13346-020-00874-6. Cited: in: : PMID: 33188495.
Mehta PP, Dhapte-Pawar VS. Novel and Evolving Therapies for COVID-19 Related Pulmonary Complications. American Journal of the Medical Sciences. 2021;361:557–566. doi: 10.1016/j.amjms.2021.02.019. Cited: in: : PMID: 33640363.
Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. European Respiratory Journal. 2020;56. doi: 10.1183/13993003.02108-2020. Cited: in: : PMID: 32269089.
https://www.healthline.com/health/copd/drugs.
Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database of Systematic Reviews. 2015;2015. doi: 10.1002/14651858.CD009552.pub3. Cited: in: : PMID: 26391969.
Hanania NA, Donohue JF, Nelson H, Sciarappa K, Goodwin E, Baumgartner RA, Hanrahan JP. The safety and efficacy of arformoterol and formoterol in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2010;7:17–31. doi: 10.3109/15412550903499498. Cited: in: : PMID: 20214460.
Keating GM, McCormack PL. Salmeterol/fluticasone propionate: A review of its use in the treatment of chronic obstructive pulmonary disease. Drugs. 2007;67:2383–2405. doi: 10.2165/00003495-200767160-00006. Cited: in: : PMID: 17983257.
Heo YA. Budesonide/Glycopyrronium/Formoterol: A Review in COPD. Drugs. 2021;81:1411–1422. doi: 10.1007/s40265-021-01562-6. Cited: in: : PMID: 34342835.
Cazzola M, Rogliani P, Stolz D, Matera MG. Pharmacological treatment and current controversies in COPD. F1000Res. 2019;8. doi: 10.12688/f1000research.19811.1. Cited: in: : PMID: 31508197.
Lavorini F, Fontana GA, Usmani OS. New inhaler devices - The good, the bad and the ugly. Respiration. 2014;88:3–15. doi: 10.1159/000363390. Cited: in: : PMID: 24902629.
Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: Technology update. Medical Devices: Evidence and Research. 2015;8:131–139. doi: 10.2147/MDER.S48888. Cited: in: : PMID: 25709510.
Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56:600–612. doi: 10.1046/j.1365-2125.2003.01893.x. Cited: in: : PMID: 14616419.
Park H, Otte A, Park K. Evolution of drug delivery systems: From 1950 to 2020 and beyond. Journal of Controlled Release. 2022;342:53–65. doi: 10.1016/j.jconrel.2021.12.030. Cited: in: : PMID: 34971694.
Adepu S, Ramakrishna S. Controlled drug delivery systems: Current status and future directions. Molecules. 2021;26. doi: 10.3390/molecules26195905. Cited: in: : PMID: 34641447.
Hardinge M, Rutter H, Velardo C, Shah SA, Williams V, Tarassenko L, Farmer A. Using a mobile health application to support self-management in chronic obstructive pulmonary disease: A six-month cohort study eHealth/ telehealth/ mobile health systems, ’AC-63541e8b0e2a0d7170bcd513bb89d0cf. BMC Med Inform Decis Mak. 2015;15. doi: 10.1186/s12911-015-0171-5. Cited: in: : PMID: 26084626.
https://clinicaltrials.gov/search?intr=bronchodilators%20in%20the%20treatment%20of%20COPD.
Miravitlles M, Acharya S, Aggarwal B, Fernandes FLA, Jardim JR, Juthong S, Levy G, Sivori M, Dreyse J. Clinical Concepts for Triple Therapy Use in Patients with COPD: A Delphi Consensus. International Journal of COPD. 2023;18:1853–1866. doi: 10.2147/COPD.S424128. Cited: in: : PMID: 37662490.
Kato M, Tomii K, Hashimoto K, Nezu Y, Ishii T, Jones CE, Kilbride S, Gross AS, Clifton CS, Lipson DA. The IMPACT study – single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: Efficacy and safety in a Japanese population. International Journal of COPD. 2019;14:2849–2861. doi: 10.2147/COPD.S226601. Cited: in: : PMID: 31839705.
Tan DJ, van Geffen WH, Walters EH. Impact of Triple Therapy vs Dual Bronchodilator Therapy on Mortality Rates in COPD. Chest. 2024;165:e158–e159. doi: 10.1016/j.chest.2023.12.033. Cited: in: : PMID: 38724158.
Esteban C, Arostegui I, Aramburu A, Moraza J, Aburto M, Aizpiri S, Chasco L, Quintana JM. Changes in health-related quality of life as a marker in the prognosis in COPD patients. ERJ Open Res. 2022;8. doi: 10.1183/23120541.00181-2021.
Published
How to Cite
Issue
Section
Copyright (c) 2024 PREETHI S., PRAVEEN HALAGALI, SURYA CS, VIKAS JAIN
This work is licensed under a Creative Commons Attribution 4.0 International License.
